Abvc Biopharma Inc (ABVC) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $661.3K

ABVC ranks #9090 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ABVC is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

15 institutions disclose a position in ABVC, but none treat it as a major bet — even Vanguard Capital Management LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

ABVC reported a net loss of $7.9M over the trailing twelve months.

• Not yet profitable — net loss of $7.9M over the trailing twelve months
• Revenue grew 155.9% year over year
• Net income declined year over year, from -$3.3M to -$7.9M
• Operating cash flow was negative, using $3.0M in cash
• Current ratio of 0.41x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.70x equity — within a conventional range